David Arterburn's main research focus is on finding safe, effective, and innovative ways to treat obesity. He is a general internist and health services researcher with a passionate commitment to helping individuals and families make treatment decisions that align with their values while sustaining their health over the long haul.
A national leader in obesity research, Dr. Arterburn joined Group Health Research Institute (GHRI) in 2006 to forge a new program of research spanning behavioral, pharmaceutical, and bariatric surgical care. Before joining GHRI, he published important findings on the epidemic nature and rising cost of obesity in the United States. Because tackling the obesity crisis requires a menu of treatment options, Dr. Arterburn's current research covers a broad range, including policy-level interventions for health plans, pharmaco-epidemiology, pharmacogenetics, the long-term outcomes of bariatric surgery, and shared decision making related to elective surgery. With the support of the Informed Medical Decisions Foundation, for which he serves as a medical editor, he has collaborated with Group Health's specialty leadership to implement and evaluate a new initiative to promote shared decision making around elective surgical care with video-based patient decision aids. The approach shows great promise for simultaneously improving the quality and lowering the costs of health care.
Dr. Arterburn's prior research in obesity pharmacotherapy has had a significant impact on clinical practice guidelines issued by the Department of Veterans Affairs (VA), the U.S. Preventive Services Task Force, the Agency for Healthcare Research and Quality, and the American College of Physicians. Dr. Arterburn is past chair of the Adult Obesity Measurement Advisory Panel sponsored by the National Committee on Quality Assurance, founding chair of the Obesity Society's Health Services Research Section, and past chair of Health Care Systems Research Network (HCSRN)'s Obesity Special Interest Group. He is also an affiliate associate professor in the University of Washington (UW) Department of Medicine. Dr. Arterburn is excited to continue his multidisciplinary work with these and other colleagues from the HCSRN, the UW, and the VA.
Bariatric surgery; health services research; economics and risk adjustment; pharmaceutical outcomes research
Obesity prevention and control
Pharmaco-epidemiology, pharmacogenetics, pharmaceutical outcomes research
Shared decision making
Feigelson HS, McMullen CK, Madrid S, Sterrett AT, Powers JD, Blum-Barnett E, Pawloski PA, Ziegenfuss JY, Quinn VP, Arterburn DE, Corley DA. Optimizing patient-reported outcome and risk factor reporting from cancer survivors: a randomized trial of four different survey methods among colorectal cancer survivors. J Cancer Surviv. 2017 Jan 13. doi: 10.1007/s11764-017-0596-1. [Epub ahead of print]. PubMed
Hsu C, Liss DT, Frosch DL, Westbrook EO, Arterburn D. Exploring provider reactions to decision aid distribution and shared decision making: lessons from two specialties. Med Decis Making. 2017;37(1):113-126. Epub 2016 Oct 6. PubMed
Maciejewski ML, Arterburn DE, Van Scoyoc L, Smith VA, Yancy WS Jr, Weidenbacher HJ, Livingston EH, Olsen MK. Bariatric surgery and long-term durability of weight loss. JAMA Surg. 2016 Aug 31. doi: 10.1001/jamasurg.2016.2317 [Epub ahead of print]. PubMed
Young DR, Waitzfelder BA, Arterburn D, Nichols GA, Ferrara A, Koebnick C, Yamamoto A, Daley MF, Sherwood NE, Horberg MA, Cromwell L, Lewis KH. The Patient Outcomes Research To Advance Learning (PORTAL) network adult overweight/obesity cohort: development and description. JMIR Res Protoc. 2016 Jun 15;5(2):e87. doi: 10.2196/resprot.5589. PubMed
Coleman KJ, Haneuse S, Johnson E, Bogart A, Fisher D, O'Connor PJ, Sherwood NE, Sidney S, Theis MK, Anau J, Schroeder EB, O'Brien R, Arterburn D. Long-term microvascular disease outcomes in patients with type 2 diabetes after bariatric surgery: evidence for the legacy effect of surgery. Diabetes Care. 2016 Jun 6. pii: dc160194. [Epub ahead of print]. PubMed
With funding from the Partnership for Innovation, GHRI is evaluating a new technology-based lifestyle program designed by Group Health bariatric surgeons.
Read about it in News and Events.
Weight loss persisted for 10 years with Roux-en-Y gastric bypass in Dr. Arterburn’s large multisite study of veterans.
Read it in Healthy Findings.
Research at Group Health points to bupropion (Wellbutrin) as first choice for overweight and obese patients with depression.
Read it in News and Events.
Study leader Dr. David Arterburn will use PCORnet, new national clinical research network, to speed results.
Read it in News and Events.
Seattle Times, Jan 6, 2015